Articles

Three specific factors explained why these patients have a higher risk of CHD events….

A new drug target for obesity and diabetes may be on the horizon….

Can insulin pumps reduce glycemic variability in type 1 diabetes?… A new cross-sectional observational cohort study looked at continuous subcutaneous insulin infusion (CSII), aka insulin pump, versus multiple daily injections (MDI) to determine which insulin delivery system resulted in less blood glucose variability in type 1 pediatric diabetes patients. Large …

Systematic review relates information regarding the link between memory and statin use….

Weekly vitamin D supplements may help curb pain and depression….

Can age at first pregnancy increase your risk of developing diabetes?…

What’s New on the Horizon? Heather Good, Doctor of Pharmacy, Candidate University of Florida Sodium-glucose co-transporter 2 (SGLT2) inhibitors, the first drugs to actually eliminate glucose from the body, are paving the way for a new wave of diabetes treatment options. Canagliflozin (Invokana®) took the U.S. market by storm when …

Can basal insulin can make a difference?… 

Once-weekly exenatide shows benefit in type 2 diabetes patients…. 

Minimizing hypoglycemia in type 2 diabetes patients…. Hypoglycemia is a common problem among patients taking combinations of insulin and sulfonylureas and may be a limiting factor in diabetes therapy management. Hypoglycemia is defined by the American Diabetes Association (ADA) as a plasma glucose of 79mg/dL. (3.9mmol/L) or less; however most people …